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ABSTRACT
Background. Intraoperative blood cell salvage and auto-
transfusion (IBSA) during liver transplantation (LT) for
hepatocellular carcinoma (HCC) is controversial for con-
cern regarding adversely impacting oncologic outcomes.
Objective. We aimed to evaluate the long-term oncologic
outcomes of patients who underwent LT with incidentally
discovered HCC who received IBSA compared with those
who did not receive IBSA.
Methods. Patients undergoing LT (January 2001–October
2018) with incidental HCC on explant pathology were
retrospectively identified. A 1:1 propensity score matching
(PSM) was performed. HCC recurrence and patient sur-
vival were compared. Kaplan–Meier survival analyses
were performed, and univariable Cox proportional hazard
analyses were performed for risks of recurrence and death.
Results. Overall, 110 patients were identified (IBSA,
n = 76 [69.1%]; non-IBSA, n = 34 [30.9%]). Before
matching, the groups were similar in terms of demo-
graphics, transplant, and tumor characteristics. Overall
survival was similar for IBSA and non-IBSA at 1, 3, and
5 years (96.0%, 88.4%, 83.0% vs. 97.1%, 91.1%, 87.8%,
respectively; p = 0.79). Similarly, the recurrence rate at 1,
3, and 5 years was not statistically different (IBSA 0%,
1.8%, 1.8% vs. non-IBSA 0%, 3.2%, 3.2%, respectively;
p = 0.55). After 1:1 matching (26 IBSA, 26 non-IBSA),
Cox proportional hazard analysis demonstrated similar risk
of death and recurrence between the groups (IBSA hazard
ratio [HR] of death 1.26, 95% confidence interval [CI]
0.52–3.05, p = 0.61; and HR of recurrence 2.64, 95% CI
0.28–25.30, p = 0.40).
Conclusions. IBSA does not appear to adversely impact
oncologic outcomes in patients undergoing LT with inci-
dental HCC. This evidence further supports the need for
randomized trials evaluating the impact of IBSA use in LT
for HCC.
Blood loss during liver transplantation (LT) often
necessitates transfusion. Intraoperative blood cell salvage
and autotransfusion (IBSA) is frequently deployed in LT to
avoid or decrease allogeneic transfusion use. Allogeneic
blood products have many drawbacks, including the
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association with increased morbidity and mortality,1,2
increased cost, infectious exposure, and antibody forma-
tion.3 IBSA mitigates many of these risks and has several
advantages over traditional allogeneic blood transfusions in
terms of avoidance of immunomodulation and antibody
formation, cost effectiveness, and also a decrease in a
recipient’s exposure to transfusion-related infections.3
LT offers curative-intent potential for patients with
hepatocellular carcinoma (HCC) who meet the strict
selection criteria, such as the Milan criteria.4 In addition,
LT also corrects any underlying cirrhosis. HCC is the
leading indication for LT at many centers.5,6 Despite the
near routine need for transfusion during LT, IBSA is rarely
used in LT for HCC due to the potential risk of dissemi-
nating cancer cells to the patient when blood loss is
salvaged and autotransfused. Therefore, HCC patients
undergoing LT at many centers receive allogeneic blood
products exclusively.
Several studies, primarily in Asia, have demonstrated no
adverse outcomes in overall survival or recurrence for
patients receiving IBSA during LT for HCC compared with
those who do not receive IBSA.7–11 Several studies in
urologic and gynecologic oncology surgery also have
shown no adverse oncologic outcomes with the use of
IBSA.12–14 Furthermore, IBSA use in hepatic surgery has
been evaluated and found to be safe, reduces the allogeneic
blood transfusion rate, and may even promote survival
compared with allogeneic transfusion.15,16 Currently, there
is a paucity of data from North American LT centers
regarding oncologic outcomes with IBSA use during LT
for HCC. Therefore, in many North American LT centers,
the use of IBSA during LT for HCC continues to be con-
troversial for concerns of adversely impacting oncologic
outcomes.
Despite the lack of IBSA use in LT for HCC, incidental
HCC on explant pathology following LT is common,
especially in patients with viral hepatitis-related cirrhosis.
Therefore, in centers that utilize IBSA during LT, patients
with incidental HCC may receive IBSA inadvertently.
Therefore, we sought to evaluate the long-term oncologic
outcomes of patients who underwent LT with incidentally
discovered HCC on final explant pathology who received
IBSA, compared with a similar group of patients with
incidental HCC who did not receive IBSA, to assess the
overall oncologic risks.
METHODS
This study was approved by our institutional Research
Ethics Board (REB; REB#15-9989) and a waiver of
informed consent was obtained.
Study Population
We assessed adults (C18 years) who underwent LT
between January 2001 and October 2018 at our institution.
Patients were followed until March 2020. All patients were
listed and underwent LT for indications other than HCC
but had HCC diagnosed incidentally on the liver explant
specimen. At our institution, IBSA is available and used in
every non-cancer LT; however, not all patients from whom
blood is salvaged have blood autotransfused (e.g. volume
overload or low blood volume salvaged). Patients were
grouped into IBSA and non-IBSA groups depending on
whether they received salvage blood autotransfusion during
the LT.
We recorded patients’ age, sex, etiology of liver disease,
Model for End-Stage Liver Disease (MELD) score at LT,
Child–Pugh score at LT, serum a-fetoprotein (AFP) at LT,
time on the waitlist, amount and type of blood products
transfused (intra- and postoperatively [up to 48 h]), type of
allograft (deceased vs. living donor), preoperative hemo-
globin (g/L), platelets (*1000) and international normalized
ratio (INR), intraoperative estimated blood loss (L), warm
ischemic time (WIT; minutes), cold ischemia time (CIT;
minutes), and previous abdominal surgery. AFP was cate-
gorized to reflect clinically relevant categories (ng/mL,
\20, 20–99, 100–999, [1000). Explant pathology char-
acteristics included the number of tumors, size of the
largest tumor, microvascular invasion, and tumor differ-
entiation. Tumor differentiation was defined according to
the modified Edmondson criteria.17 This study complies
with the Strengthening the Reporting of Observational
Studies in Epidemiology (STROBE) statement for retro-
spective studies.18
Process of Intraoperative Blood Cell Salvage
and Autotransfusion and Institutional Policy
Blood salvage was performed using Cell Saver 5
(Haemonetics, Braintree, MA, USA). Shed blood from the
operative field was suctioned to the reservoir of the device
containing anticoagulant. If sufficient blood was collected,
it underwent centrifugation and washing and was processed
to a red blood cell (RBC) concentrate (approximately
50–80% hematocrit). Once the re-infusion bag reached
500 mL, the salvaged blood was autotransfused for a target
intraoperative blood hemoglobin of 80 g/L. No leukocyte
depletion filter was used in the process of cell salvage. Per
our institutional policy, IBSA is contraindicated in any
surgical procedure involving HCC.
T. Ivanics et al.
Outcome Measures
The study’s primary endpoints were the impact of
intraoperative IBSA on post-LT survival and HCC tumor
recurrence.
Propensity Score Matching
A propensity score was constructed based on the pre-
dicted probability of IBSA receipt using logistic regression.
This was performed to control for the effect of confounding
and represents a method for addressing selection bias.
Covariates selected were variables that are associated with
degree of liver dysfunction and blood loss during LT.19–24
Given that the variables are associated with blood loss, by
extension we posited that they would also be associated
with IBSA receipt (blood cell salvage autotransfusion).
These included preoperative hemoglobin,20,22 MELD,19,20
preoperative platelet count,24 preoperative INR,24 Child–
Pugh score,21,25 allograft type, WIT,19 previous abdominal
surgery,21 CIT,25 and recipient age.19 Matching was then
performed using these covariates in a 1:1 ratio between
IBSA and non-IBSA receipt using a greedy, nearest-
neighbor matching algorithm with no replacement.26
Matching quality was evaluated with standardized mean
differences between the treated and control groups. A
difference \10% was used as indicative of a negligible
imbalance between groups.27
Statistical Analysis
Descriptive data were expressed using medians and
interquartile range (IQR) and compared using Student’s t-
tests and Mann–Whitney U tests. Categorical variables
were expressed using number percentages and compared
using Chi-square and Fisher’s exact tests. Disease-free
survival was defined as patients being alive without
recurrence at last follow-up. Disease-free and overall sur-
vival were estimated using the Kaplan–Meier method, and
groups were compared using log-rank tests. Univariable
Cox proportional hazard regression models were con-
structed after matching to evaluate the impact of IBSA on
mortality and recurrence. A multivariable model was not
performed as propensity score matching (PSM) was
selected as the method for confounding adjustment. All
two-sided p-values \0.05 were considered statistically
significant. Statistical analyses were performed using SAS
version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Study Population and Pathology
Between January 2001 and October 2018, 110 LT
patients with incidental HCC on explant pathology were
identified. Of these, 76 (69.1%) received IBSA and 34
(30.9%) did not. The median blood volume autotransfused
in the IBSA group was 750 mL (IQR 500–1480). The two
groups were similar in age, sex, etiology of liver disease,
serum AFP at LT, Child–Pugh score, and MELD score at
LT. The most common etiology of liver disease was hep-
atitis C virus (HCV) cirrhosis in both groups (IBSA 42.1%
vs. non-IBSA 52.9%; p = 0.86). The time on the LT
waitlist was similar between the groups (median number of
months [IQR] IBSA 4.7 [1.9–14.5] vs. non-IBSA 3.4
[1.4–9.3]; p = 0.35). The units of allogeneic pRBC and
platelets transfused were similar between groups. The
majority of patients received a deceased donor liver graft
(71.8%), and the proportions of deceased donor liver
transplant (DDLT) and living donor liver transplant
(LDLT) patients were similar between the IBSA and non-
IBSA groups. The amount and types of blood products
used intra- and postoperatively were similar between the
groups (Table 1)
Explant Pathology
Both groups were similar in terms of tumor number
(median [IQR] IBSA 11,2 vs. non-IBSA 11,2; p = 0.50),
size of the largest tumor (median, cm [IQR] IBSA 1.2
[0.8–1.6] vs. non-IBSA 1.5 [1.0–1.8]; p = 0.11), rates of
microvascular invasion (IBSA 7.9% vs. non-IBSA 8.8%),
and tumor differentiation (moderate differentiation IBSA
69.3% vs. non-IBSA 83.3%; p = 0.40) (Table 1)
Survival Analysis in the Unmatched Cohort
The post-LT follow-up was similar between groups
(median months [IQR] IBSA 68.4 [36.3–92.9] vs. non-
IBSA 70.8 [17.3–105.1]; p = 0.94). Overall survival was
similar at 1, 3, and 5 years (IBSA 96.0%, 88.4%, 83.0% vs.
non-IBSA 97.1%, 91.1%, 87.8%, respectively; p = 0.79).
Similarly, recurrence rate was not statistically different at
1, 3, and 5 years (IBSA 0%, 1.8%, 1.8% vs. non-IBSA 0%,
3.2%, 3.2%, respectively; p = 0.55) (Figs. 1 and 2). Of the
four patients who recurred, two had intrahepatic recurrence
(both in the IBSA group) and two had extrahepatic recur-
rence (both in the non-IBSA group).
Cell Salvage in Incidental HCC
TABLE 1 Descriptive statistics in the IBSA and no IBSA transfusion groups before matching
Overall
(n = 110)
IBSA (n = 76
(69.1%))





Demographics and tumor characteristics
Age, years [median (IQR)] 55.5 (50.9–60.9) 56.0 (51.6–60.9) 54.6 (49.5–60.2) 0.63 0.016
Sex, male [n (%)] 91 (82.7) 61 (80.3) 30 (88.2) 0.31 0.23
Etiology of cirrhosis [n (%)] 0.86
Hepatitis C infection 50 (45.5) 32 (42.1) 18 (52.9) 0.28
Hepatitis B infection 11 (10.0) 8 (10.5) 3 (8.8) 0.06
NASH 18 (16.4) 14 (18.4) 4 (11.8) 0.16
Acute liver disease 22 (20.0) 16 (21.1) 6 (17.7) 0.11
Others 9 (8.2) 6 (7.9) 3 (8.8) 0.08
Serum AFP at transplant, ng/mL [n (%)] 0.85 0.002
\ 20 99 (90.8) 69 (92.0) 30 (88.2)
20–99 7 (6.4) 4 (5.3) 3 (8.8)
100–999 3 (2.8) 2 (2.7) 1 (3.0)
[ 1000 0 (0.0) 0 (0.0) 0 (0.0)
Child–Pugh score [n (%)] 0.84
A 2 (1.8) 1 (1.3) 1 (3.0) 0.11
B 36 (32.7) 25 (32.9) 11 (32.4) 0.02
C 72 (65.5) 50 (65.8) 22 (64.7) 0.02
MELD score at transplant [median (IQR)] 22 (18–26) 21 (17–25) 22.5 (20–27) 0.28 0.20
Previous abdominal surgery [n (%)] 27 (24.5) 21 (27.6) 6 (17.7) 0.26 0.22
Liver transplant characteristics
Hemoglobin pretransplant, g/L [median (IQR)]b 99 (86–111) 99.5 (87–112) 95.5 (82–109) 0.24 0.19
Platelets pretransplant, times 1000 [median (IQR)]b 68 (47–92) 70.5 (48–93.5) 67 (42–88) 0.73 0.06
INR pretransplant [median (IQR)]b 1.8 (1.5–2.3) 1.8 (1.5–2.3) 1.9 (1.6–2.5) 0.20 0.22
Estimated blood loss, ml [median (IQR)]b 2.6 (1.5–5) 3.2 (2–5.5) 2 (0–4) 0.002 0.57
Postoperative transfusion (up to 48 h post-transplant)
[n (%)]
68 (61.8) 49 (64.5) 19 (55.9) 0.39 0.26
RBC 36 (32.7) 23 (30.3) 13 (38.2) 0.41 0.14
FFP 23 (20.9) 14 (18.4) 9 (26.5) 0.34 0.27
Platelets 24 (21.8) 15 (19.7) 9 (26.5) 0.43 0.23
Cryoprecipitate 2 (1.8) 1 (1.3) 1 (2.9) 0.52 0.12
Albumin 52 (47.3) 39 (51.3) 13 (38.2) 0.20 0.32
Number of postoperative RBC transfusions 0 (0–1) 0 (0–1) 0 (0–1.5) 0.23 0.61
Number of postoperative FFP transfusions 0 (0–0) 0 (0–0) 0 (0–1.5) 0.19 0.56
Number of postoperative platelet transfusions 0 (0–0) 0 (0–0) 0 (0–1.5) 0.33 0.31
Number of postoperative cryoprecipitate transfusions 0 (0–0) 0 (0–0) 0 (0–0) 0.53 0.26
Number of postoperative albumin transfusions 0 (0–2) 1 (0–2) 0 (0–2) 0.36 0.26
WIT, min [median (IQR)]b 50 (41.5–59.0) 47.5 (40.5–59) 53 (47–58) 0.34 0.25
CIT, min [median (IQR)]b 358 (166–502) 358 (184–502) 339 (158–520) 0.92 0.03
Operation duration, min [median (IQR)]b 488 (420–570) 483 (420–570) 493 (411–546) 0.70 0.02
Time on the waiting list, months [median (IQR)] 3.8 (1.7–13.9) 4.7 (1.9–14.5) 3.4 (1.4–9.3) 0.35 0.10
Units of intraoperative pRBC transfusions [median
(IQR)]
5 (3–8) 5 (3–7) 6 (4–10) 0.05 0.38
Units of intraoperative platelet transfusions [median
(IQR)]
2 (1–5) 2 (1–5) 2 (1–5) 0.83 0.17
Blood given through cell saver, mL [median (IQR)] 750 (500–1480) 750 (500–1480) – – –




IBSA (n = 76
(69.1%))





Type of graft [n (%)] 0.12
Deceased donor liver graft 79 (71.8) 58 (76.3) 21 (61.8) 0.26
Living donor liver graft 31 (28.2) 18 (23.7) 13 (38.2) 0.26
Explant pathology characteristics
Number of viable tumors at explant [median (IQR)] 1 (1–2) 1 (1–2) 1 (1–2) 0.77 0.16
Size of the largest viable tumor at explant, cm [median
(IQR)]
1.2 (1.0–1.7) 1.2 (0.8–1.6) 1.5 (1.0–1.8) 0.11 0.29
Microvascular invasion [n (%)] 9 (8.18) 6 (7.9) 3 (8.8) 1.0 0.03
Tumor differentiation [n (%)] 0.40
Well differentiated 25 (23.8) 20 (26.7) 5 (16.7) 0.46
Moderately differentiated 77 (73.3) 52 (69.3) 25 (83.3) 0.21
Poorly differentiated 3 (2.7) 3 (4.0) 0 (0) –
Outcomes
Tumor recurrence [n (%)] 4 (3.6) 2 (5.9) 2 (2.6) 0.59
Time to recurrence, months [median (IQR)] 46.7
(29.1–101.7)
84.2 (27.1–141.2) 46.7 (31.2–62.2) 1.0
Death [n (%)] 30 (27.3) 18 (23.7) 12 (35.3) 0.25
Time to death, months [median (IQR)] 70.8 (36.3–92.9) 68.4 (36.3–92.9) 70.8 (17.3–105.1) 0.94
AFP a-fetoprotein, CIT cold ischemia time, FFP fresh frozen plasma, IBSA intraoperative blood salvage autotransfusion, INR international
normalized ratio, IQR interquartile range, MELD Model for End-stage Liver Disease, NASH non-alcoholic steatohepatitis, pRBC packed red
blood cells, RBC red blood cells, SMD standardized mean difference, WIT warm ischemia time
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FIG. 1 Recurrence based on IBSA use in the unmatched cohort.
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FIG. 2 Overall survival based on IBSA use in the unmatched cohort.
IBSA intraoperative blood cell salvage and autotransfusion
Cell Salvage in Incidental HCC
Matched Cohort
Following PSM, 26 IBSA patients were matched with
26 non-IBSA patients. The standardized mean difference
was \10% between groups (Table 2). Univariable Cox
proportional hazard regression for risk of death demon-
strated an equivalent risk between groups in the matched
cohort (IBSA [ref. non-IBSA] HR 1.26, 95% CI 0.52–3.05;
p = 0.61). The recurrence risk was also similar between
groups (IBSA [ref. non-IBSA] HR 2.64, 95% CI
0.28–25.30; p = 0.40).
DISCUSSION
These findings demonstrate that IBSA use does not
significantly impact oncologic outcomes of overall survival
or recurrence in patients undergoing LT with incidentally
discovered HCC. Moreover, the observed recurrence rates
in IBSA do not exceed what has been traditionally accepted
for post-LT HCC recurrence.
In the 1990s, Hansen et al. detected circulating tumor
cells in a majority (93.4%) of 61 cancer patients during
various oncologic surgeries. These cells demonstrated
proliferative capacity, invasiveness, and tumorigenicity. As
a consequence, caution was expressed towards autotrans-
fusion of blood during oncologic surgery.28 The process of
IBSA was subsequently refined with leukocyte depletion
filters, which could remove tumor cells and reduce the risk
of tumor re-introduction during the cell-salvage process,
although the efficacy of leukocyte depletion filters remains
unproven by high-level prospective clinical data.29 Gwak
et al. evaluated the ability of one leukocyte depletion filter
to remove HCC tumor cells.29 Six groups of progressively
increasing amounts of tumor cells were passed through the
filter and subsequently evaluated using polymerase chain
reaction on the resuspended pellet that remained after the
filtration process.29 The authors noted that the filter could
remove tumor cells, although its effectiveness diminished
with increasing HCC cell counts.29 Nonetheless, several
subsequent retrospective studies, mostly from Asia, have
further demonstrated no increase in the risk of cancer
recurrence with a leukocyte depletion filter in the process
of IBSA use during LT for HCC, suggesting that either the
number of tumor cells that enter the filtration process are
few, the tumor cells that may re-enter the circulation do not
harbor the potential for seeding and metastasis develop-
ment, or that the process of autotransfusion does not alter
the natural biological course of the disease.8–11,30 The
largest of these was by Han et al. from Korea, who per-
formed a PSM analysis of LDLT recipients in whom the
indication for LT was HCC.7 Of 397 matched LDLT HCC
patients, there were 222 IBSA patients and 97 non-IBSA
patients.7 There were no differences in the cumulative
HCC recurrence rate at 1, 2, and 5 years (IBSA 10.8%,
14.9%, 20.3% vs. 10.4%, 19.1%, and 24.1%, respec-
tively).7 Similarly, the groups were equivalent in risk for
overall, intrahepatic, or extrahepatic recurrence.7 In con-
trast to many of the previously reported studies, our series
did not use leukocyte depletion filters for any of the cases.
The studies that show equivalent oncologic outcomes
between the IBSA and non-IBSA groups offer further
evidence of oncologic safety of IBSA use during LT for
HCC and suggest the urgent need for a prospective trial.
From these studies, contraindication of IBSA during sur-
gical procedures for HCC is unwarranted. The adverse
oncologic effects of IBSA are mostly theoretical, and many
of the abovementioned retrospective studies have failed to
corroborate this association. Nonetheless, due to the low-
level evidence afforded by their study designs, the devel-
opment of safe clinical guidelines has been precluded. A
clinical randomized control trial would address these lim-
itations; however, it is further hindered by ethical
constraints that oncologic safety cannot be guaranteed,
again based on low-level evidence.
Moreover, likely reflective of the long study period and
high center LT volume, our study presents the largest
cohort of incidental HCCs after LT to date.31–33 In a pre-
vious report by Pérez et al., oncologic outcomes of 27
incidental HCC patients after LT were compared with 141
patients with known HCC.32 Both groups had similar rates
of multinodular disease, vascular invasion, and tumor dif-
ferentiation.32 Although there was no difference between
the risk of tumor recurrence on adjusted analysis, incidental
HCC represented an independent risk for post-LT mortal-
ity. In that study, the 5-year recurrence-free survival was
79.7%, which was lower than the 5-year recurrence-free
survival rates reported in our study of 98.2% and 96.8% in
the IBSA and non-IBSA groups, respectively. Our results
are also comparable with reported post-LT recurrence in
the current literature, ranging from 9.8 to 17.3%.34,35 Our
study did not specifically aim to compare the outcomes of
incidental HCC after LT with patients known to have HCC
before LT; however, it does highlight that the oncologic
risk, despite overall favorable tumor characteristics, is not
negligible. As incidental HCCs carry a low risk of recur-
rence, conclusions cannot be directly extrapolated to
patients with known HCC at the time of LT, who have a
more significant tumor burden. Moreover, the presence and
role of circulating tumor cells in patients with early HCC
remains to be elucidated. Nonetheless, the results presented
herein offer evidence for oncologic safety of cell-saver use,
at least for the incidental HCCs, and further reinforce the
need for a randomized clinical trial for higher-level evi-
dence to drive potential practice change.
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TABLE 2 Descriptive statistics in the IBSA and no IBSA transfusion groups after matching
IBSA [n = 26] No IBSA [n = 26] p-valuea SMD
Demographics and tumor characteristics
Age, years [median (IQR)] 54.9 (52.6–61.6) 54.6 (50.0–59.5) 0.58 0.1
Sex, male [n (%)] 18 (69.2) 22 (84.6) 0.19 0.44
Etiology of cirrhosis [n (%)] 0.96
Hepatitis C infection 12 (46.2) 13 (50) 0.08
Hepatitis B infection 3 (11.5) 3 (11.5) 0.00
NASH 5 (15.4) 4 (15.4) 0.10
Acute liver disease 4 (15.4) 5 (19.2) 0.10
Others 2 (4.7) 1 (3.9) 0.14
Serum AFP at transplant, ng/mL [n (%)] 0.36 0.30
\ 20 24 (92.3) 23 (88.5)
0–99 1 (3.8) 3 (11.5)
100–999 1 (3.8) 0 (0)
[ 1000 – –
Child–Pugh score [n (%)] 0.95
A 1 (3.85) 1 (3.85) 0.00
B 10 (38.5) 9 (34.6) 0.08
C 15 (57.7) 16 (61.5) 0.08
MELD score at transplant [median (IQR)] 21 (18–23) 22 (18–28) 0.32 0.10
Previous abdominal surgery [n (%)] 8 (30.8) 5 (19.2) 0.34 0.10
Liver transplant characteristics
Hemoglobin pretransplant, g/L [median (IQR)]b 101 (89–121) 99 (91–113) 0.28 0.11
Platelets pretransplant, times 1000 [median (IQR)]b 66.5 (52–98) 67.5 (46–88) 0.46 0.10
INR pretransplant [median (IQR)]b 1.8 (1.5–2.3) 1.8 (1.6–2.3) 0.64 0.02
Estimated blood loss, mL [median (IQR)]b 2 (1.5–3) 2 (0.8–4) 0.58 0.05
Postoperative transfusion [n (%)] 13 (50) 16 (61.5) 0.40 0.23
RBC 7 (26.9) 11 (42.3) 0.24 0.32
FFP 3 (11.5) 8 (30.8) 0.09 0.46
Platelets 5 (19.2) 9 (34.6) 0.21 0.37
Cryoprecipitate 0 (0) 1 (3.8) 0.31 0.26
Albumin 10 (38.5) 12 (46.2) 0.57 0.16
Number of postoperative RBC transfusions 0 (0–1) 0 (0–2) 0.12 0.34
Number of postoperative FFP transfusions 0 (0–0) 0 (0–2) 0.06 0.37
Number of postoperative platelet transfusions 0 (0–0) 0 (0–2) 0.24 0.29
Number of postoperative cryoprecipitate transfusions 0 (0–0) 0 (0–0) 0.32 0.11
Number of postoperative albumin transfusions 0 (0–2) 0 (0–2) 0.74 0.07
WIT, mins [median (IQR)]b 46 (40–56) 53 (47–57) 0.07 0.06
CIT, mins [median (IQR)]b 372 (120–497) 408 (191–540) 0.64 0.07
Operation duration, mins [median (IQR)]b 470 (410–570) 465 (400–510) 0.52 0.23
Time on the waiting list, months [median (IQR)] 4.9 (2.3–13.3) 3.8 (1.5–9.3) 0.53 0.14
Units of pRBC transfusion [median (IQR)] 3 (2–6) 6 (4–10) 0.007 0.41
Units of platelets transfusion [median (IQR)] 1 (0–3) 2 (1–5) 0.19 0.01
Blood given through cell saver, mL [median (IQR)] 550 (400–830) – – –
Type of graft [n (%)] 1.0
Deceased donor liver graft 19 (73.1) 19 (73.1) 0.00
Living donor liver graft 7 (26.9) 7 (26.9) 0.00
Explant pathology characteristics
Number of viable tumors at explant [median (IQR)] 1 (1–2) 1 (1–2) 0.76 0.29
Cell Salvage in Incidental HCC
Despite accumulating retrospective evidence, IBSA
remains contraindicated in many North American LT
centers (including our institution). Hence, the only possible
study population available to address our clinical question
was limited to LT patients with incidental HCCs on
explant. These patients predictably had favorable tumor
characteristics; they were generally small, solitary, and had
low rates of microvascular invasion. In our analysis, no
statistical difference in tumor characteristics was observed
between patients who received IBSA and those who did
not. Nonetheless, to the best of our knowledge, this is the
first report of IBSA use in North America.
Generally, IBSA is used during LT to reduce the
exposure to the recipient of allogeneic blood products,
which represent a scarce resource and carry the potential of
increasing morbidity and mortality.36,37 At University
Health Network, approximately 40–50% of LTs performed
every year are for patients with HCC. During LT for HCC,
significant blood loss is common and frequently requires
blood transfusion.23,38,39 At our institution, 72.9% of
patients receive an allogenic blood transfusion, either
intraoperatively or within the first 48 h after the LT for
HCC (unpublished data). This number can potentially be
reduced with the more widespread use of IBSA. Allogeneic
blood transfusions may lead to transfusion-associated
immunomodulation and, in some studies, are associated
with an increased risk of HCC recurrence following liver
resection; however, this remains controversial.1,2,40,41
IBSA affords advantages over traditional allogeneic blood
transfusions by not only potentially mitigating these factors
and limiting the immunomodulatory effect, which can be
detrimental, but possibly also by improving cost effec-
tiveness.3 IBSA can also decrease a recipient’s exposure to
viruses, protozoa, and prions.3 Taken into combination,
increased use of IBSA for HCC, particularly in centers
where this indication represents the largest proportion of
patients undergoing LT, may decrease the amount of
allogeneic blood transfusions, and possibly morbidity and
mortality, without adversely impacting oncologic
outcomes.
Limitations
This study is limited by its retrospective and non-ran-
domized design, with the potential for selection and
misclassification bias. Given the study’s single-institutional
nature, the results may not be generalizable to other cen-
ters. Despite this being the largest study in North America
to date, the number of patients is still small, limiting the
study’s statistical power to detect differences between
groups examined. Moreover, although adjustments have
been made for known covariates that may have confounded
the results, there is potential for residual confounding and
type 1 error.
CONCLUSION
IBSA does not appear to adversely impact oncologic
outcomes in patients undergoing LT with incidental HCC
compared with those not receiving IBSA. While the
recurrence risk in both the IBSA and non-IBSA groups is
not negligible, the rates are low and similar. This evidence
supports the further need for randomized trials evaluating
the impact of IBSA use in LT for HCC.
TABLE 2 continued
IBSA [n = 26] No IBSA [n = 26] p-valuea SMD
Size of the largest viable tumor at explant, cm
[median (IQR)]
1.15 (0.7–1.6) 1.5 (1.2–2.0) 0.03 0.37
Microvascular invasion [n (%)] 1 (3.8) 3 (11.5) 0.29 0.27
Tumor differentiation [n (%)] 0.10
Well differentiated 8 (30.8) 2 (9.1) 0.62
Moderately differentiated 17 (65.4) 20 (90.9) 0.26
Poorly differentiated 1 (3.8) 0 (0) –
AFP a-fetoprotein, CIT cold ischemia time, FFP fresh frozen plasma, IBSA intraoperative blood salvage autotransfusion, INR international
normalized ratio, IQR interquartile range, MELD Model for End-stage Liver Disease, NASH non-alcoholic steatohepatitis, pRBC packed red
blood cells, RBC red blood cells, SMD standardized mean difference, WIT warm ischemia time
aP-value corresponds to a two-sided Student t-test comparison between patients who received cell saver transfusion and patients who did not
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